![]() |
市場調查報告書
商品編碼
2170416
一次性注射器市場機會、成長要素、產業趨勢分析及2026-2035年預測。Disposable Syringe Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 |
||||||
預計到 2025 年,一次性注射器市場規模將超過 152 億美元,年複合成長率為 6.1%,到 2035 年將達到 275.8 億美元。
重複注射、疫苗接種計劃和醫療機構安全要求推動了市場需求。雖然安全性高的醫療設備在嚴格的醫療機構中應用日益廣泛,但傳統產品在公共衛生系統中仍發揮著至關重要的作用,其可負擔性和大規模供應是影響競標規格的關鍵因素。
| 市場範圍 | |
|---|---|
| 開始年份 | 2025 |
| 預測期 | 2026-2035 |
| 上市時的市場規模 | 152億美元 |
| 預測金額 | 275.8億美元 |
| 複合年成長率 | 6.1% |
慢性病治療需持續消耗胰島素、生物製藥、抗凝血劑、癌症治療及其他相關治療用品。需求遍及醫院、門診和居家照護,從而減少了對擇期手術的依賴。疫苗接種透過集中競標和宣傳活動活動,形成了不同的採購模式。自動失效功能和防止重複使用的設計必須符合專案政策,因此,除了價格之外,經認證的供給能力和交貨系統也至關重要。額外的疫苗接種和補種工作會形成集中採購期,這有利於擁有完善庫存和分銷系統的供應商。安全法規是另一個結構性促進因素,它要求醫療機構應對暴露風險並提供適當的醫療設備。醫療機構在產品合格過程中會評估操作性能、訓練、操作和處置方法。這些因素促進了對檢驗的安全機制和可靠供應品的採購。因此,商業性成長是持續臨床應用、公共衛生相關競標和監管合規三者共同作用的結果,這要求供應商既要滿足成本受限的大宗採購項目,又要滿足合規要求更高的醫療機構。
從產品類型來看,預計到2025年,傳統注射器將佔銷售額的48.0%。其熟悉的設計符合許多公共衛生部門客戶的預算和競標要求。成熟的採購關係和簡單的生產流程也確保了傳統注射器在大批量採購專案中繼續發揮作用。然而,安全要求正在推動產品組合的變化,尤其是在受監管的醫療保健管道中。在價格合理且規格合適的關鍵選擇標準下,傳統注射器仍然發揮著至關重要的作用。進入這一領域的供應商必須保持可靠的供應鏈和具有競爭力的生產能力,因為大規模專案不僅重視器械成本,也重視持續交付訂單的能力。該細分市場的商業性地位反映了對易於獲取的注射耗材的持續需求與日益普及的更專業的安全規範之間的關聯。
依應用領域分類,預計2025年,藥物管理領域的市場規模將達到60.8億美元。慢性病管理需要在診所、醫院和門診中重複給藥。胰島素、生物製藥製劑、抗凝血療法和其他持續治療催生了對適用於日常護理的可靠醫療設備的需求。治療場所的轉移並未消除注射的需求,採購目標也已擴及急性護理機構之外。製造商可以透過認證產品和可靠的通路來滿足這些需求。商業性價值在於整個治療流程的一致性和可近性,尤其是在患者需要持續給藥的情況下,醫療保健提供者會根據持續護理的實際需求而非偶爾治療的採購來評估耗材。
預計到2035年,北美一次性注射器市場規模將達到92.2億美元。臨床應用、成熟的醫院採購體係以及既定的安全標準是推動該地區市場規模成長的主要因素。醫療採購負責人在選擇醫療設備時,優先考慮產品檢驗、可靠的供應和服務。這些標準支撐了對安全型產品的需求,使得供應商對產品的要求不再侷限於單價。供應商必須將認證產品與可靠的供應管道結合,並連接到成熟的採購網路。因此,該地區的商機包括持續的臨床應用以及在醫療機構中取代傳統產品。客戶關係以及滿足嚴格採購標準的能力將影響供應商能否與醫院和其他醫療機構簽訂高價值合約。
預計到2025年,貝克頓·迪金森公司(BD)將佔據全球市場收入的16%。其注射劑產品系列以及與醫院的緊密合作關係,使其能夠同時滿足傳統醫療器材和注重安全性的醫療設備的需求。豐富的產品線使其能夠靈活應對監管醫療設備和公共衛生項目不同的採購優先事項。客戶可以針對多種醫療設備需求評估成熟的供應商,而無需單獨採購產品類型。公司的地位不僅體現在其產品設計上,也體現在其生產規模和醫療保健採購管道上。當買家需要用於持續臨床應用的檢驗醫療設備以及需要可預測競標執行的大規模專案時,廣泛的銷售管道覆蓋和可靠的供應商業性。
市場的主要參與者包括貝朗醫療(B. Braun Melsungen)、Terumo Corporation(Terumo Corporation)、尼普洛株式會社(Nipro Corporation)和印度斯坦注射器及醫療器材公司(Hindustan Syringes and Medical Devices,簡稱HMD)。貝朗醫療將歐洲的生產和分銷體系與廣泛的醫院供應網路結合。Terumo Corporation提供國際注射產品,並致力於開發以安全為導向的產品。尼普洛滿足大量採購、自有品牌和價格敏感型採購需求,而HMD則專注於用於免疫接種的一次性及自動失效醫療設備。競爭格局取決於資格、生產連續性、分銷管道和安全能力。全球供應商服務於要求嚴苛的醫療機構,而區域製造商則在以成本為導向的競標中競爭。除了產品價格之外,買家也越來越重視整體供應的可靠性,可靠的執行和穩定的供應對於維持商業性關係至關重要。
The Disposable Syringe Market exceeded USD 15.2 billion in 2025 and is projected to grow at 6.1% CAGR to reach USD 27.58 billion by 2035. Repeated injections, immunization programs, and institutional safety requirements support demand. Purchasing increasingly includes safety-engineered devices in regulated care settings, while conventional products remain relevant to public-health systems where affordability and large-volume supply shape tender specifications.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $15.2 Billion |
| Forecast Value | $27.58 Billion |
| CAGR | 6.1% |
Chronic care creates recurring consumption through insulin, biologics, anticoagulation, oncology, and associated treatment needs. Demand extends across hospitals, outpatient services, and home care, reducing dependence on elective procedures. Vaccination provides a different procurement pattern through centralized tenders and campaign schedules. Auto-disable and reuse-prevention designs must meet program policies, making qualified capacity and delivery execution important alongside price. Additional vaccines and catch-up initiatives can create concentrated purchasing periods that favor suppliers with ready inventory and distribution. Safety regulation adds another structural driver by requiring healthcare employers to address exposure and provide suitable devices. Institutions evaluate activation performance, training, handling, and disposal as part of product qualification. These factors encourage procurement of validated safety mechanisms and dependable supplies. Commercial growth therefore combines recurrent clinical use with public-health tenders and regulatory conversion, requiring suppliers to serve both cost-constrained volume programs and higher-compliance institutional accounts.
Based on product type, conventional syringes represented 48.0% of revenue in 2025. Familiar designs meet the budgets and tender requirements of many public-health customers. Established purchasing relationships and straightforward manufacturing support their continuing role in broad-volume programs. Safety requirements nevertheless encourage a changing mix, particularly within regulated institutional channels. Conventional devices retain relevance where affordability and suitable specifications guide selection. Suppliers serving the category must sustain reliable availability and competitive production, because large programs evaluate their ability to fulfill orders consistently as well as device cost. The segment's commercial position reflects the continued need for accessible injection supplies alongside growing adoption of more specialized safety configurations.
By application, drug delivery contributed USD 6.08 billion in 2025. Chronic disease management supports repeated administration across clinics, hospitals, and outpatient settings. Insulin, biologic therapy, anticoagulation, and other continuing treatments create demand for dependable devices that fit recurring care. The shift in treatment locations does not remove injection requirements, allowing purchasing to extend beyond acute facilities. Manufacturers can address these needs through qualified products and reliable channels. Commercial relevance depends on consistency and access across treatment routines, particularly when patients require sustained administration and providers evaluate supplies through the practical requirements of ongoing care rather than occasional procedure purchasing.
The North America disposable syringe market is projected to reach USD 9.22 billion by 2035. Clinical use, mature hospital purchasing, and established safety expectations support regional value. Institutional buyers emphasize validation, resilient supply, and service when selecting devices. These criteria sustain demand for safety-engineered products and create requirements beyond basic unit pricing. Suppliers must combine qualified mechanisms with dependable delivery into established procurement networks. Regional opportunity consequently includes continuing clinical volume and institutional replacement of conventional formats, with customer relationships and the ability to meet rigorous purchasing standards influencing access to higher-value contracts across hospitals and other care settings.
Becton, Dickinson and Company (BD) represented 16% of global market revenue during 2025. Its injection portfolio and hospital relationships support participation in both conventional and safety-device demand. This breadth provides flexibility across regulated institutions and public-health programs with different purchasing priorities. Customers can evaluate an established supplier through several device needs rather than organize every product category separately. The company's position reflects manufacturing scale and access to healthcare procurement as well as product design. Broad channel coverage and reliable supply are commercially significant when buyers need validated devices for recurring clinical use or large programs requiring predictable tender fulfillment.
Some of the major players in this market are B. Braun Melsungen, Terumo Corporation, Nipro Corporation, and Hindustan Syringes and Medical Devices (HMD). B. Braun combines European manufacturing and distribution with wider hospital-supply relationships. Terumo provides international injection products and develops safety-oriented offerings. Nipro serves high-volume, private-label, and price-sensitive purchasing, while HMD emphasizes disposable and auto-disable devices for immunization. Competition depends on qualification, manufacturing continuity, distribution, and safety capabilities. Global suppliers address demanding institutions, while regional producers compete in cost-conscious tenders. Buyers increasingly assess overall supply reliability alongside product price, making execution and consistent availability central to maintaining commercial relationships.